In syngeneic mouse tumor models, Tiragolumab surrogate antibodies activated TAMs, monocytes, and DCs via FCγR engagement, leading to a transition of CD8+ T cells from an exhausted effector-like phenotype to a memory-like state. Here, FCGR2A is linked to neoplasm.